Business Context and Reporting Period
This Form 8-K filing by Anthem, Inc. (now Elevance Health, Inc.) reports a significant capital market transaction. The report date is May 12, 2015, covering an event that occurred on May 6, 2015, regarding the closing of a sale of Equity Units.
Key Financial Metrics
- Total Proceeds: The Company sold an aggregate of 25,000,000 Equity Units for a stated amount of $1.250 billion.
- Net Proceeds: The Company anticipates receiving approximately $1,225.1 million after deducting underwriting discounts and offering expenses.
- Debt Repurchase: As of May 6, 2015, the Company agreed to repurchase approximately $700.5 million aggregate principal amount of its 2.750% Senior Convertible Debentures due 2042.
- Instrument Structure: Each Corporate Unit has a stated amount of $50 and consists of a purchase contract for common stock and a 5% interest in $1,000 principal amount of 1.90% Remarketable Subordinated Notes due 2028.
- Contract Adjustments: Holders are entitled to quarterly contract adjustment payments at a rate of 3.35% per year of the stated amount.
Material Changes
The primary material change is the execution of a $1.250 billion equity-linked financing. This transaction involves the issuance of new subordinated notes and purchase contracts, altering the company's capital structure. Additionally, the company is actively reducing its existing debt load by repurchasing a significant portion of its 2042 Senior Convertible Debentures.
Outlook, Management Commentary, and Risks
- Use of Proceeds: Net proceeds are designated for general corporate purposes, specifically including the repurchase of outstanding 2.750% Senior Convertible Debentures due 2042.
- Settlement Date: The purchase contract settlement date is set for May 1, 2018, subject to earlier termination or settlement.
- Collateral and Pledges: The Notes are pledged as collateral to secure the obligation to purchase common stock. Holders may elect to create "Treasury Units" by substituting pledged U.S. Treasury securities.
- Underwriter Relationships: Certain affiliates of the underwriters (Credit Suisse and Merrill Lynch) are participants in the Company's $2.0 billion revolving credit facility and provide other banking services.
Investor Verification Checklist
- Verify the final net proceeds received after all transaction costs.
- Confirm the exact volume of 2.750% Senior Convertible Debentures repurchased using the proceeds.
- Review the terms of the 1.90% Remarketable Subordinated Notes due 2028 for remarketing conditions.
- Monitor the settlement of the purchase contracts on or before May 1, 2018.
- Assess the impact of the 3.35% contract adjustment payments on future cash flow obligations.